ICON Appoints New Chief Medical Officer
05 May 2020 - 6:30PM
Business Wire
ICON announces the appointment of Dr.
Kristen K. Buck as the new Chief Medical Officer (CMO)
ICON plc, (NASDAQ: ICLR) a leading global provider of
drug and device development and commercialisation services to the
pharmaceutical, biotechnology and medical device industries, today
announced that Dr. Kristen K. Buck has been appointed Chief Medical
Officer.
Kristen joins ICON from Optum Insights (part of the United
Healthcare group) where she was SVP & Chief of Clinical
Development. Kristen led the clinical operations and regulatory
groups to create a Real-World Evidence and Outcomes clinical trial
business. Her experience ranges over multiple therapy areas
including GI, neuroscience, dermatology, ophthalmology, oncology,
cardiovascular/metabolic, immunology, renal, women’s health, orphan
diseases, liver, and psychiatry.
Kristen is a board certified and licenced physician from the
Pennsylvania State University School of Medicine, and completed her
Internship and Residency in Internal Medicine at Abington Memorial
Hospital, before working as a primary care practitioner in a
private practice. From there Kristen moved to the FDA in the GI and
Hematology division, where she was responsible for reviewing
efficacy and safety for all new indications, as well as
post-marketing safety for over 40 drugs. Kristen spent time working
at AstraZeneca in clinical development and in its Innovative
Medicines group.
“We are delighted to appoint Dr Kristen Buck as our new Chief
Medical Officer,” said Steve Cutler, ICON’s Chief Executive
Officer. “Kristen’s appointment will improve coordination and
access to the significant medical and scientific resources and
expertise we have at ICON. We will focus this expertise on helping
our customers negotiate challenges, as we constantly strive to
improve our services and respond to the latest issues and
developments in science and medicine.”
“I’m excited to be leading ICON’s position on clinical
development trends, and reviewing and advising on our medical risks
as the world wrestles with the Covid-19 pandemic,” said Dr. Buck.
“Patient centricity is ever more important in the current climate
and I look forward to working with the wider ICON team to broaden
our insights and expand our expertise.”
About ICON plc
ICON plc is a global provider of drug and device development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently operates from 98
locations in 40 countries and has approximately 15,100 employees as
of March 31, 2020. Further information is available at
www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005415/en/
ICON Media Contact Gareth Arnold Weber Shandwick +44
(0)7870 516043 garnold@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2024 to May 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From May 2023 to May 2024